SGD Pharma has entered into a Franco-American OEM collaboration with Prince Sterilization Services, LLC to validate Ready-to-Use (RTU) Type I glass primary packaging solutions for the North American market. As the first outcome of this partnership, the companies have introduced the My Sterinity Nasal platform, a flexible cleaned vial range under SGD Pharma’s My Sterinity RTU platform. Built on the company’s U-Save Type I vials, the solution is designed to support the growing segment of nasal drug delivery.
The My Sterinity Nasal platform represents the initial launch stemming from the collaboration, combining SGD Pharma’s expertise in Type I glass manufacturing with Prince’s sterilization capabilities. The vials will initially be offered in 3.5ml, 7.5ml and 10ml formats, available in both clear and amber glass. Key attributes include controlled particulate and endotoxin levels, biologically inert Type I sterile glass that eliminates the need for preservatives, validated sterility assurance, compatibility with standard preservative-free nasal pump systems, and double-bagged tray packaging for RTU presentation. Production will take place at SGD Pharma’s Saint-Quentin-La-Motte (SQLM) facility in northern France, while Prince will manage washing, depyrogenation and sterilization processes in North America, creating a regional supply chain aligned with U.S. biopharmaceutical requirements.
The global nasal market, valued at €9 billion and exceeding 2 billion units, has traditionally been dominated by plastic materials, accounting for approximately 88% of usage. However, increasing demand for advanced therapies is shifting focus toward glass, which provides enhanced chemical inertness, barrier protection and long-term biocompatibility. These characteristics are essential for maintaining product integrity, reducing adsorption risks and ensuring sterility, particularly in chronic-use treatments. As therapeutic applications expand into areas such as Alzheimer’s, Parkinson’s, multiple sclerosis and depression, the role of high-performance primary packaging in nasal drug delivery continues to gain importance.
Carole Grassi, Chief Commercial Marketing & Innovation Officer, SGD Pharma comments: “Our collaboration with Prince marks an important milestone in SGD Pharma’s innovation growth strategy for North America. The My Sterinity Nasal platform represents a major step forward in high-value nasal drug delivery, and our collaboration with Prince unlocks immediate US-qualified capacity for biopharma customers scaling complex nasal therapy programs. This is more than a product launch, it is a validated supply chain ready to support qualification, clinical trials and commercial launch with unmatched speed and reliability.”
Daniel Prince, Ph.D., CEO of Prince adds: “SGD Pharma’s Type I glass expertise combined with our quality focused and flexible RTU & sterilization platform creates the gold standard for sterile nasal packaging. Prince’s recent US qualification means we can now deliver ready-to-use, terminally sterilized My Sterinity Nasal vials in timelines that match domestic and international customer development cycles and exceed quality requirements.”
